Skip to main content
Figure 2 | BMC Neurology

Figure 2

From: Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties

Figure 2

25-OH- vitamin D serum levels. Serum 25-OH-D (25-hydroxy-vitamin D) was measured at baseline, 3, 6 and 12 month using a chemiluminescent immunoassay. The high dose supplementation resulted in significantly higher serum 25-OH-D levels compared to low dose throughout the follow up (P < 0.001). With high dose, 25-OH-D levels were significantly above baseline at all time points (P ≤ 0.01), while low dose resulted in significantly increased 25-OH-D levels compared to baseline only at 3 months (P = 0.006) and at 6 months (P = 0.04).

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us